Veracyte (VCYT)

Executive Summary

Veracyte (VCYT) is a leading genomic diagnostics company that provides molecular insights to guide cancer care across thyroid, prostate, bladder, breast, and lung cancers. Founded in 2008 and headquartered in South San Francisco, the company has established a portfolio of high-performing tests, including Afirma for thyroid nodules, Decipher for prostate and bladder cancers, and Percepta for lung cancer. These tests enable physicians to make more informed, personalized treatment decisions, reducing unnecessary procedures and improving patient outcomes. Veracyte’s revenue is driven by a combination of test volumes, reimbursement expansion, and strategic partnerships, with a strong focus on value-based healthcare. The company’s tests are supported by extensive clinical validation and have garnered broad adoption among urologists, endocrinologists, and oncologists. With a valuation of approximately $2.6 billion and 5 commercial products, Veracyte is well-positioned to capture a significant share of the growing precision oncology diagnostics market. Veracyte’s growth strategy centers on expanding test indications, driving reimbursement coverage, and advancing its pipeline of new genomic tests. The company continues to invest in research and development to deepen its understanding of cancer biology and identify novel biomarkers. Key near-term opportunities include broadening the Decipher Prostate test into early-stage risk stratification, which could unlock a larger patient population, and pursuing label expansions for existing tests. Additionally, Veracyte is leveraging its large genomic database to develop liquid biopsy and minimal residual disease (MRD) assays, though these are earlier stage. The company faces competition from other molecular diagnostics firms, but its proprietary algorithms and strong clinical data provide a competitive moat. Overall, Veracyte is a compelling growth story in precision oncology, with a proven commercial model and multiple levers for expansion.

Upcoming Catalysts (preview)

• Q3 2026Expansion of Decipher Prostate into early-stage risk stratification75% success
• Q4 2026Positive clinical data for Decipher Bladder Cancer leading to guideline inclusion65% success
• Q2 2026FDA 510(k) clearance for next-generation Percepta Lung test80% success